The phase III RADIANT-4 trial evaluated the efficacy of everolimus (mTOR inhibitor) in comparison to placebo in patients with advanced, well-differentiated, G1/G2 gastrointestinal and lung NETs. The gene discussed is MTOR; the disease is lung neuroendocrine neoplasm.